Many Sources of Upside for WCRX

Analysts at Morgan Stanley initiate coverage of Warner Chilcott (NASDAQ: WCRX) with an “overweight” rating. The target price for WCRX is set to $32.

According to Morgan Stanley, the market seems to under-appreciate WCRX’s growth potential. Warner Chilcott is likely to exceed the market expectations for its 2010-2012 EPS. Asacol and Actonel would be converted into versions with longer patent lives.

Morgan Stanley expects WCRX’s SG&A expenses to decline during 2015, as the Sanofi co-promotion agreement ends. The company is likely to witness 10% EPS growth during 2010-2013 and a five-year growth of 4%. The FCF yield for the company for 2010 is forecasted to be 13%.


There are 1 comments
Please note that comments may take up to one hour before they get published on the site. Please check back later to see your comments.

this stock is up and still

this stock is up and still moving based on the good news. Hope it reached $32 much sooner than anticipated


for best penny stock picks daily - www.bit.ly/lookat9

Post new comment

The content of this field is kept private and will not be shown publicly.